GlassScriptPhysician profile
Tamara Kwon Johnson
NPI 1073245544
$2,131.57
in general payments reported to CMS, 2019-2025
17 companies · $601 in 2025
The $601 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.16 · 2023: $299 · 2024: $1,208 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,108.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $318.83 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $223.72 | 2023-2025 | Spravato, Invega Sustenna, Risperdal |
| Otsuka America Pharmaceutical, INC. | $196.23 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $177.96 | 2024-2025 | Fanapt |
| Alkermes, INC. | $155.26 | 2022-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.13 | 2024-2025 | Caplyta |
| Corium, LLC | $130.65 | 2023-2024 | Azstarys |
| Lundbeck LLC | $126.78 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $119.48 | 2023-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $106.93 | 2024-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $89.06 | 2024-2025 | Uzedy |
| Neurocrine Biosciences, INC. | $84.10 | 2024 | Ingrezza |
| Bausch Health US, LLC | $77.85 | 2024-2025 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $68.96 | 2024 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $46.17 | 2023-2024 | Jornay Pm |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $44.22 | 2024 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $23.24 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.